KYTX
Kyverna Therapeutics, Inc.
$9.68
+0.52 (+5.68%)
At close · Jul 7
Market Cap
$588.50M
Shares
60,795,212
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Gregory Martini | Chief Financial Officer | Appointed | 2026-05-18 |